【摘要】：目的： 研究Polo樣激酶1 (polo-like kinase 1, PLK1)在喉鱗狀細(xì)胞癌(laryngeal squamous cell carcinoma, LSCC)中的表達(dá)情況及與臨床病理因素的關(guān)系,探討PLK1在LSCC發(fā)生發(fā)展中的作用及臨床意義。 方法： 收集和篩選臨床資料,對符合條件的資料進(jìn)行分組,分別用免疫組化和Western blot兩種方法檢測PLK1在LSCC和癌旁組織中的表達(dá)情況。用免疫組織化學(xué)的有70例LSCC和21例癌旁組織,用Western blot檢測23對新鮮LSCC和癌旁組織。并對70例LSCC患者進(jìn)行術(shù)后隨訪,研究PLK1的表達(dá)與LSCC的預(yù)后關(guān)系。用統(tǒng)計學(xué)的方法對所得數(shù)據(jù)進(jìn)行統(tǒng)計學(xué)分析。 結(jié)果： 1.免疫組化結(jié)果顯示：PLK1蛋白陽性表達(dá)具有異質(zhì)性,胞漿和胞核均有表達(dá),胞漿呈棕色,胞核呈深棕色或棕褐色,以胞漿著色為主,LSCC和癌旁組織中總的陽性表達(dá)率分別為68.6%和28.6%。前者高于后者,差異有統(tǒng)計學(xué)意義(P0.05)。 2. Western blot結(jié)果顯示：在23對LSCC及癌旁組織新鮮標(biāo)本中,有4對為LSCC和癌旁組織共同陽性表達(dá)；有12對為LSCC陽性表達(dá),癌旁組織為陰性表達(dá)；1對為LCSS表達(dá)為陰性,而癌旁組織陽性表達(dá)；6對組織為LSCC和癌旁均無陽性表達(dá)。PLK1在LSCC陽性表達(dá)16例,陽性率69.6%；癌旁組織陽性表達(dá)5例,陽性率21.7%,前者高于后者,差異有統(tǒng)計學(xué)意義(P0.05)。 3. PLK1蛋白表達(dá)與LSCC臨床病理特征的關(guān)系：免疫組化和western blot實驗結(jié)果分析均顯示,PLK1的表達(dá)與LSCC的分期和淋巴結(jié)轉(zhuǎn)移及臨床分期相關(guān),T3-T4期腫瘤高于T1-T2期,臨床Ⅲ-Ⅵ期的腫瘤高于臨床Ⅰ-Ⅱ期,伴有淋巴結(jié)轉(zhuǎn)移的腫瘤患者高于無淋巴結(jié)轉(zhuǎn)移的患者,均有統(tǒng)計學(xué)意義(P0.05)；而PLK1的表達(dá)與患者的性別、LSCC的部位以及細(xì)胞分化程度無統(tǒng)計學(xué)相關(guān)(P0.05)。 4.PLK1蛋白表達(dá)與預(yù)后的關(guān)系：對70例LSCC患者在術(shù)后進(jìn)行隨訪(截止時間為患者死亡或研究截止日期),隨訪時間在5年以上,其中失訪4人,隨訪率94.3%。結(jié)果PLK1陽性患者的5年總生存率為37.8%(17/45),而陰性者為71.4%(15/21),差異有統(tǒng)計學(xué)意義(P0.05)。 結(jié)論： 1.PLK1在LSCC中的表達(dá)明顯高于癌旁組織,表明在LSCC中存在著PLK1蛋白的過表達(dá)現(xiàn)象,提示PLK1是LSCC的一個腫瘤標(biāo)記物； 2. PLK1的表達(dá)與腫瘤的分期、淋巴結(jié)轉(zhuǎn)移正向相關(guān),提示PLK1的表達(dá)可能與LSCC的惡性行為有關(guān)。PLK1的表達(dá)與患者的性別、LSCC的原發(fā)部位和細(xì)胞分化程度無關(guān)。 3. PLK1的表達(dá)和LSCC患者的預(yù)后相關(guān),PLK1陽性患者的預(yù)后更差,PLK1有可能成為LSCC患者基因治療的靶點和一個預(yù)后指標(biāo)。
[Abstract]:Objective: to investigate the expression of polo-like kinase 1 (PLK1) in laryngeal squamous cell carcinoma (LSCC) and its relationship with clinicopathological factors, and to explore the role of PLK1 in the pathogenesis and development of LSCC and its clinical significance. Methods: the clinical data were collected and screened, and the eligible data were divided into groups. The expression of PLK1 in LSCC and adjacent tissues was detected by immunohistochemistry and Western blot respectively. There were 70 cases of LSCC and 21 cases of paracancerous tissues by immunohistochemistry. 23 pairs of fresh LSCC and adjacent tissues were detected by Western blot. 70 patients with LSCC were followed up after operation to study the relationship between the expression of PLK1 and the prognosis of LSCC. The data were analyzed statistically by statistical method. Results: 1. The results of immunohistochemistry showed that the positive expression of WPLK1 protein was heterogeneity, the cytoplasm and nucleus were brown, and the cytoplasm was dark brown or brown. The total positive expression rates in LSCC and adjacent tissues were 68.6% and 28.6%, respectively. The former was higher than the latter, the difference was statistically significant (P0.05). Western blot results showed that in 23 pairs of fresh LSCC and adjacent tissues, 4 pairs were co-positive for LSCC and paracancerous tissues, 12 pairs were LSCC positive, and 1 pair was negative for LCSS expression in paracancerous tissues. There were 16 cases of positive expression of LSCC in LSCC and 16 cases of positive expression of PLK1 in paracancerous tissues, and 5 cases of positive expression in paracancerous tissues with a positive rate of 21.7%, the former being higher than that of the latter, the difference being statistically significant (P0.05). The relationship between the expression of PLK1 protein and clinicopathological features of LSCC: the results of immunohistochemistry and western blot assay showed that the expression of pPLK1 was higher than that of T1-T2 in the stage of LSCC, lymph node metastasis and clinical stage. The clinical stage 鈪，

本文編號：2149026